
| China: | Chinese Cancer Genome Consortium |
| |
| China: | Ministry of Science and Technology |
| China: | National High Technology Research and Development Program (“863”Program) of China |
| |
| China: | National Natural Science Foundation of China |
![]() |
|
China: Beijing Cancer Hospital/Institute
China: Chinese Cancer Genome Consortium
China: Peking University School of Oncology
| China: | Beijing Cancer Hospital/Institute |
| Peking University School of Oncology |
Primary gastric cancer samples were collected from tumor bank of Beijing Cancer Hospital/Insititute, as approved by the Research Ethics Board at the Hospital/Institute. Specimens were surgically resected, snap-frozen and stored at -80°C. Through estimation by H&E staining and pre-screening by two pathologists,tumor nuclei proportion in chosed tumor sample was > 60-80%.
| China: | BGI-Shenzhen |
We will do whole exome sequencing using next generation sequncing technology mainly in Illumina GA II. Data processing will be performed by independently developed software. We will call multi-type mutations and find their relationship with cancer biology.
| China: | BGI-Shenzhen |
Study of copy number variation and structure variation by low depth whole genome sequencing, transcriptome analysis by RNA-seq, methylome analysis by MeDIP-seq and micro RNA analysis; all performed using Illumina GA II sequencing and complementary informatic work.
| China: | Beijing Cancer Hospital/Institute |
| BGI-Shenzhen | |
| Chinese Cancer Genome Consortium | |
| Peking University School of Oncology |
We are using self-developed LIMS system and real-time quality control system , coordinating with the automated data processing pipeline on BLC (Bioinfomatic Linux Cluster) to deal with the basic data analyzing and managing. For advanced anlysis and specific scientific goals, we will design certain software or construct new database.
In view of its high prevalence in China and the existence of possible interacting environmental factors, China will focus on gastric cancer as a part of the International Cancer Genome Consortium activities. In particular, China will focus both on Intestinal-type and diffuse-type cancer. The major reasons for selection of gastric cancer are:
• It is the most common cancer with high incidence and poor prognosis in China, most of cancer patients to be diagnostic too later to cure.
• Intestinal- type and diffuse-type cancer is different in clinical pathological features and gene expression profiling.
• About 50-80% of cancers have the high risk of recurrence and metastasis following creative resection,.
• Precancerous lesion including intestinal metaplasia (IM) and dysplasia (Dys) has high incidence and have a high risk to be transformed to malignance.
• It is fundamental to analyze genomic changes for discovering biomarkers to detect gastric cancer early and to predict prognosis.
Working Plan
(A) Samples & Collection
(A.1) Tumor samples were defined using Lauren and WHO criteria.
(A.2) Tissues from gastric cancer patients, each (a) previously untreated, (b) 500mg of tumor and mached normal tissues collected based on NCI and ICGC guidelines, (c) >60-80% of collected tissue should have viable-appearing tumour cells on histological assessment and <5% necrotic cells.
(A.3) Systematical collection of clinical data and follow-up, the patient therapy based on NCCN, guidelines, (Clinical practice in oncology: gastric cancer/Chinese version).
(B) Sample Characterization
Histopathology: (a) Optical images to be stored, (b) To be reviewed by 2 senior pathologists
(C) DNA/RNA Isolation and Sample Storage
(C.1) Isolate high-quality DNA
(C.2) Isolate high-quality RNA
(C.3) Freeze, using NCI guidelines for biorepositories (2006)
(D) Genomics Analyses
(D.1) SNP Array genotyping: To identify CNVs LOH, etc.
(D.2) Exon capture and DNA deep-resequencing
(E) Data Management
(E.1) Creation of a database of project-specific workflows
(E.2) Creation of an integrated data warehouse and server.
(E.3) Creation of a protocol for dispatch of data on a regular basis for upload to the ICGC Backend Server (as required under ICGC guidelines)
(F) Statistical Analysis
Development of protocols and methodologies for an integrative statistical analysis
• Huanming Yang
• Youyong Lu
Bladder Cancer - Invasive Urothelial Bladder Cancer
Bone Cancer - Osteosarcoma / chondrosarcoma / rare subtypes 
Breast Cancer - Subtype defined by an amplification of the HER2 gene
Breast Cancer - Ductal carcinoma
Breast cancer - Asian phenotype
Pediatric Brain Tumors - Medulloblasma & Pediatric Pilocytic Astrocytoma
Brain Cancer - Pediatric Medulloblastoma
Oral Cancer - Gingivobuccal
Thyroid Cancer - Papillary thyroid carcinoma
Chronic Lymphocytic Leukemia - CLL with mutated and unmutated IgVH
Liver Cancer - Hepatocellular carcinoma (Virus associated)
Ovarian Cancer - Serous cystadenocarcinoma
Rare Pancreatic Tumors - Enteropancreatic endocrine tumors and rare pancreatic exocrine tumors
